Brain tumour genetic network signatures of survival
Open Access
- 4 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (11) , 4736-4754
Abstract
Tumour heterogeneity is increasingly recognized as a major obstacle to therapeutic success across neuro-oncology. Gliomas are characterized by distinct combinations of genetic and epigenetic alterations, resulting in complex interactions across multiple molecular pathways. Predicting disease evolution and prescribing individually optimal treatment requires statistical models complex enough to capture the intricate (epi)genetic structure underpinning oncogenesis. Here, we formalize this task as the inference of distinct patterns of connectivity within hierarchical latent representations of genetic networks. Evaluating multi-institutional clinical, genetic and outcome data from 4023 glioma patients over 14 years, across 12 countries, we employ Bayesian generative stochastic block modelling to reveal a hierarchical network structure of tumour genetics spanning molecularly confirmed glioblastoma, IDH-wildtype; oligodendroglioma, IDH-mutant and 1p/19q codeleted; and astrocytoma, IDH-mutant. Our findings illuminate the complex dependence between features across the genetic landscape of brain tumours and show that generative network models reveal distinct signatures of survival with better prognostic fidelity than current gold standard diagnostic categories.Keywords
All Related Versions
Funding Information
- Guarantors of Brain, the Medical Research Council
- NHS Topol Digital Fellowship
- UCLH
This publication has 107 references indexed in Scilit:
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013
- Molecular pathogenesis of IDH mutations in gliomasBrain Tumor Pathology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and OligodendrogliomasThe American Journal of Pathology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasJournal of Clinical Investigation, 2008
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- Molecular Biology of Malignant Degeneration of AstrocytomaPediatric Neurosurgery, 1996